Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

Published loading...Updated

OncoSil (ASX:OSL) puts a A$98m revenue number on a A$43m market cap

A 70% gross margin at scale reframes how the Macquarie Park manufacturing build should be valued OncoSil Medical (ASX:OSL) has dropped its mid-July investor presentation, and for a company that spent years being a regulatory story, this deck reads like a commercial one. The headline number is a A$98 million revenue opportunity from the new Sydney manufacturing facility at roughly 70% gross margin at full capacity. Against a A$43 million market c…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Stocks Down Under broke the news on Wednesday, July 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal